CTOs on the Move


 
AcelRx Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain. The Company`s product candidates, DSUVIA™ (known as ARX-04 outside of the United States) and ZALVISO®, are designed to deliver sufentanil, a strong opioid analgesic, via a non-invasive, sublingual formulation in medical supervised settings. DSUVIA is designed to deliver sublingual tablets containing 30 mcg sufentanil via a disposable, pre-filled, single-dose applicator. The Phase 3 clinical program has completed and assessed the investigational product in the treatment of moderate-to-severe acute pain in patients who had undergone surgery or ...
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million
  • www.acelrx.com
  • 351 Galveston Drive
    Redwood City, CA USA 94063
  • Phone: 650.216.3500

Executives

Name Title Contact Details

Funding

AcelRx raised $27.5M on 01/20/2021

Similar Companies

Ethica Health and Retirement Communities

Ethica Health and Retirement Communities is a Gray, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

CitiMed

CitiMed is a healthcare provider with over 100 board certified healthcare providers offering a full range of medical services, including primary care, neurosurgery, and pain management, with 20 locations in Queens, the Bronx, and White Plains.

Averion International Corporation

Averion International Corporation is a Southborough, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Kymera Therapeutics

Kymera is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system. Kymera’s proprietary targeted protein degradation platform, called Pegasus, enables us to discover highly selective small molecule protein degraders with activity against disease-causing proteins throughout the body. We believe that our small molecule protein degraders have significant advantages over existing therapies and allow us to address a large portion of the human genome that was previously intractable with traditional modalities. Kymera focuses on biological pathways that have been clinically validated but where key biological nodes/proteins have not been drugged or have been inadequately drugged. To date, we have utilized our Pegasus platform to design novel protein degraders focused in the areas of immunology-inflammation and oncology, and continue to apply our platform’s capabilities to additional therapeutic areas.

NxStage

NxStage is more than just a company; we are leading the renal revolution. By our own design, we`re at the leading edge of a movement to transform renal care. To make it simpler. To make it portable. To expand treatment options for clinicians by overcoming traditional barriers. To enhance patient freedom and fulfillment. With significant breakthroughs already behind us - and others in the pipeline - NxStage is finding itself at the forefront of dramatically improved renal care, thanks to innovative yet simple therapeutic solutions that benefit patients, caregivers, and society. Our approach – and success is inspiring patients and providers.